TipRanks
Go Ultimate55% OFF

VentriPoint Diagnostics (VPT) Price & Analysis

VPT Stock Chart & Stats

CA$0.08CA$0.00(0.00%)
At close: 4:00 PM EDT
CAD 0.08CAD 0.09CAD 0.1CAD 0.114 Aug17 Aug31 Aug14 Sep28 Sep13 Oct26 Oct
Day’s Range
CAD 0.08 - CAD 0.08
52-Week Range
CAD 0.08 - CAD 0.19
Previous Close
CAD 0.08
Volume
79.10K
Average Volume (3M)
127.56K
Market Cap
CAD 15.43M
Enterprise Value
CAD 22.72M
Total Cash (Recent Filing)
CAD 333.63K
Total Debt (Recent Filing)
CAD 2.62M
Price to Earnings (P/E)
―
Beta
-0.76
Next Earnings
Dec 02, 2026
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Sustained revenue expansion indicates growing adoption of the company’s cardiac imaging analytics and supports a larger commercial base. If maintained, this growth can improve operating leverage, strengthen market presence, and provide a foundation for eventual profitability.

High Gross Margin

The exceptionally high gross margin suggests the software-led offering has attractive underlying unit economics once operating costs are covered. This creates meaningful potential for incremental revenue to contribute strongly toward research, commercialization, and future earnings improvement.

Narrowing Losses

Improvement from materially worse margins in prior years indicates some progress toward financial stabilization. Continued reduction in losses could extend the company’s runway and allow its high-margin revenue model to translate into stronger operating performance over the next several quarters.

Bears Say

Persistent Unprofitability

Ongoing negative earnings show that the current revenue base does not yet cover operating costs, despite strong gross margins. Until the company reaches break-even, growth may require additional funding and management must convert commercial expansion into durable operating profitability.

Negative Cash Generation

Continued operating and free-cash-flow deficits mean the business is not self-funding and cash is still being consumed to support operations. This limits financial flexibility, increases dependence on capital access, and can constrain investment in product development or commercialization.

Deteriorated Capital Structure

Negative equity reflects accumulated losses that have more than offset contributed capital, while debt materially exceeds the stated asset base. This weak capital structure reduces resilience, limits financing flexibility, and increases reliance on external funding to sustain the business.

VentriPoint Diagnostics News

VPT FAQ

What was VentriPoint Diagnostics’s price range in the past 12 months?
VentriPoint Diagnostics lowest stock price was C$0.08 and its highest was C$0.19 in the past 12 months.
What is VentriPoint Diagnostics’s market cap?
VentriPoint Diagnostics’s market cap is C$15.43M.
When is VentriPoint Diagnostics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were VentriPoint Diagnostics’s earnings last quarter?
VentriPoint Diagnostics released its earnings results on Sep 01, 2026. The company reported -C$0.007 earnings per share for the quarter.
Is VentriPoint Diagnostics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does VentriPoint Diagnostics pay dividends?
VentriPoint Diagnostics does not currently pay dividends.
What is VentriPoint Diagnostics’s EPS estimate?
VentriPoint Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VentriPoint Diagnostics have?
VentriPoint Diagnostics has 192,877,940 shares outstanding.
What happened to VentriPoint Diagnostics’s price movement after its last earnings report?
VentriPoint Diagnostics reported an EPS of -C$0.007 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of VentriPoint Diagnostics?
Currently, no hedge funds are holding shares in TSE:VPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology